Characterization and adequacy of the use of radiotherapy and its trend in time
- PMID: 23199651
- DOI: 10.1016/j.radonc.2012.10.008
Characterization and adequacy of the use of radiotherapy and its trend in time
Abstract
Background and purpose: Characterization of radiotherapy activity and its trend over time. Gathering of parameters for future planning of our resources, applicable to similar population areas. Performing a clinical audit of appropriate use of radiotherapy.
Material and methods: Analysis of 9782 patients treated between 1998 and 2008. Descriptive statistics of pathologies and social/demographic characteristics. Intention of treatment. The rate of radiotherapy utilization was estimated and compared with those considered optimal. Rate of reirradiation.
Results: The average global rate of radiotherapy utilization for the period was 32.7%. It increased by 23% between 1998 and 2008, while the population of the area rose by 1.04%, equaling an average 1.13 irradiations/1000 inhabitants/year. Radiation treatment has increased by 13.6, 2.3, 1.6 and 1.06 times in patients with prostate, breast, rectal and lung cancer, respectively. Eight percent of radiotherapy treatments involve concurrent chemotherapy. The proportion of treatments with palliative intent was 18.2%. The overall underutilization of radiation therapy in our environment was an estimated 13.4%.
Conclusions: The grade of adequacy of radiation rates in relation with scientific evidence was globally considered suboptimal, especially in lung cancer. There was an upward trend of irradiation in breast and prostate cancer, tending toward rates considered optimal.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
A prospective survey of radiotherapy in Sweden.Acta Oncol. 1996;35 Suppl 6:47-56. Acta Oncol. 1996. PMID: 9154085
-
Cancer trends in Sweden until 2010.Acta Oncol. 1996;35 Suppl 6:37-45. Acta Oncol. 1996. PMID: 9154084
-
Population-based study of trends and variations in radiotherapy as part of primary treatment of cancer in the southern Netherlands between 1988 and 2006, with an emphasis on breast and rectal cancer.Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):464-71. doi: 10.1016/j.ijrobp.2008.08.074. Epub 2009 Mar 14. Int J Radiat Oncol Biol Phys. 2009. PMID: 19289268
-
Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.Ann Thorac Surg. 2004 Oct;78(4):1200-5; discussion 1206. doi: 10.1016/j.athoracsur.2004.04.085. Ann Thorac Surg. 2004. PMID: 15464470 Review.
-
Estimation of an optimal radiotherapy utilization rate for gastrointestinal carcinoma: a review of the evidence.Cancer. 2004 Aug 15;101(4):657-70. doi: 10.1002/cncr.20443. Cancer. 2004. PMID: 15305395 Review.
Cited by
-
Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects.Int J Nanomedicine. 2024 Oct 2;19:9459-9486. doi: 10.2147/IJN.S466396. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39371481 Free PMC article. Review.
-
ATR kinase activation in G1 phase facilitates the repair of ionizing radiation-induced DNA damage.Nucleic Acids Res. 2013 Dec;41(22):10334-44. doi: 10.1093/nar/gkt833. Epub 2013 Sep 14. Nucleic Acids Res. 2013. PMID: 24038466 Free PMC article.
-
Integrating nanomedicine into clinical radiotherapy regimens.Adv Drug Deliv Rev. 2019 Apr;144:35-56. doi: 10.1016/j.addr.2019.07.002. Epub 2019 Jul 4. Adv Drug Deliv Rev. 2019. PMID: 31279729 Free PMC article. Review.
-
Pattern of care in radiotherapy at a University Hospital in Spain: the RENORT project.Clin Transl Oncol. 2021 Aug;23(8):1657-1665. doi: 10.1007/s12094-021-02564-2. Epub 2021 Feb 14. Clin Transl Oncol. 2021. PMID: 33586123
-
Advanced Nitric Oxide Generating Nanomedicine for Therapeutic Applications.ACS Nano. 2023 May 23;17(10):8935-8965. doi: 10.1021/acsnano.3c02303. Epub 2023 May 1. ACS Nano. 2023. PMID: 37126728 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical